(EWTX) Edgewise Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 3.413m USD | Total Return: 133.2% in 12m
Avg Turnover: 34.2M
Warnings
Altman Z'' -15.00 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Leader
Edgewise Therapeutics (EWTX) is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for rare neuromuscular and cardiac disorders. The company’s lead candidate, sevasemten, is currently in Phase II trials targeting the underlying mechanisms of Duchenne and Becker muscular dystrophies. Its pipeline also includes early-stage programs for hypertrophic cardiomyopathy and heart failure.
Operating within the biotechnology sector, Edgewise utilizes a precision medicine business model, which seeks to mitigate risk by targeting genetically defined patient populations where the biological drivers of disease are well understood. This approach often benefits from regulatory incentives such as Orphan Drug Designation, which can provide extended market exclusivity and streamlined clinical pathways for rare disease treatments.
You can further evaluate the companys financial health and clinical milestones by reviewing the data on ValueRay.
- Sevasemten Phase 2 clinical trial data for Duchenne and Becker muscular dystrophy
- Clinical progress of EDG-7500 for hypertrophic cardiomyopathy and cardiac disorders
- Research and development spending levels impacting cash runway and burn rate
- Regulatory approval pathways and orphan drug designations for rare muscle diseases
- Future partnership milestones and licensing agreements for precision medicine pipeline
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.29 > 0.02 and ΔFCF/TA -2.41 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.29 > 3% & CFO -148.5m > Net Income -176.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 22.61 > 1.5 & < 3 |
| Outstanding Shares: last quarter (107.1m) vs 12m ago 12.60% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.47%; Δ -0.47% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.94 (Total Current Assets 509.8m - Total Current Liabilities 22.5m) / Total Assets 518.5m |
| B: -1.15 (Retained Earnings -595.4m / Total Assets 518.5m) |
| C: -0.39 (EBIT TTM -187.6m / Avg Total Assets 486.5m) |
| D: -23.52 (Book Value of Equity -595.6m / Total Liabilities 25.3m) |
| Altman-Z'' = -24.87 = D |
As of May 24, 2026, the stock is trading at USD 32.69 with a total of 607,571 shares traded.
Over the past week, the price has changed by -1.18%,
over one month by +1.65%,
over three months by +8.67% and
over the past year by +133.24%.
Edgewise Therapeutics has received a consensus analysts rating of 4.30. Therefore, it is recommended to buy EWTX.
- StrongBuy: 5
- Buy: 3
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 43.7 | 33.6% |
Revenue TTM = 0.0 USD
EBIT TTM = -187.6m USD
EBITDA TTM = -187.6m USD
Long Term Debt = 2.78m USD (estimated: total debt 3.79m - short term 1.02m)
Short Term Debt = 1.02m USD (from shortTermDebt, last quarter)
Debt = 7.78m USD (from shortLongTermDebtTotal, last quarter) + Leases 3.99m
Net Debt = -491.8m USD (calculated: Debt 7.78m - CCE 499.6m)
Enterprise Value = 2.92b USD (3.41b + Debt 7.78m - CCE 499.6m)
Interest Coverage Ratio = unknown (Ebit TTM -187.6m / Interest Expense TTM 0.0)
EV/FCF = -19.64x (Enterprise Value 2.92b / FCF TTM -148.7m)
FCF Yield = -5.09% (FCF TTM -148.7m / Enterprise Value 2.92b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 2.27m) / Revenue TTM)
Tobins Q-Ratio = 5.63 (Enterprise Value 2.92b / Total Assets 518.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 7.78m)
Taxrate = 21.0% (US default 21%)
NOPAT = -148.2m (EBIT -187.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 22.61 (Total Current Assets 509.8m / Total Current Liabilities 22.5m)
Debt / Equity = 0.02 (Debt 7.78m / totalStockholderEquity, last quarter 493.2m)
Debt / EBITDA = 2.62 (negative EBITDA) (Net Debt -491.8m / EBITDA -187.6m)
Debt / FCF = 3.31 (negative FCF - burning cash) (Net Debt -491.8m / FCF TTM -148.7m)
Total Stockholder Equity = 540.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -36.18% (Net Income -176.0m / Total Assets 518.5m)
RoE = -15.49% (Net Income TTM -176.0m / Total Stockholder Equity 1.14b)
RoCE = -16.47% (EBIT -187.6m / Capital Employed (Equity 1.14b + L.T.Debt 2.78m))
RoIC = -29.82% (negative operating profit) (NOPAT -148.2m / Invested Capital 497.0m)
WACC = 11.86% (E(3.41b)/V(3.42b) * Re(11.89%) + D(7.78m)/V(3.42b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.89% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.22 | Cagr: 25.05%
[DCF] Fair Price = unknown (Cash Flow -148.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.46 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.48 | Chg30d=+2.22% | Revisions=+11% | Analysts=10
EPS next Quarter (2026-09-30): EPS=-0.52 | Chg30d=+0.95% | Revisions=+27% | Analysts=10
EPS current Year (2026-12-31): EPS=-2.03 | Chg30d=+1.79% | Revisions=+9% | GrowthEPS=-24.7% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.33 | Chg30d=+0.33% | Revisions=+33% | GrowthEPS=-14.8% | GrowthRev=+3015.8%
[Analyst] Revisions Ratio: +33%